Results
Aurobindo Pharma Q1 FY27 Revenue Up 16% to ₹9,150 Cr
Aurobindo Pharma reported Q1 FY27 consolidated revenue growth of 16% YoY to ₹9,150 crores with an EBITDA margin of 21%.
The company completed the Lannett acquisition, strengthening its US platform in
